Background {#Sec1}
==========

Human epidermal growth factor receptor2(*HER2*) positivity is well-studied in breast cancer, while much less defined in lung cancer. Although anti-HER2 monoclonal antibody such as trastuzumab has been proven effective in breast cancer and gastric cancer \[[@CR1], [@CR2]\], the clinical trials \[[@CR3], [@CR4]\] of lung cancer including patients treated with trastuzumab combined with chemotherapy failed to demonstrate benefit in survival in HER2 IHC positive patients. Besides that, pan-HER TKI dacomitinib also showed no response in patients with HER2 amplifications in a phase II trial \[[@CR5]\].

Apart from HER2 over-expression and amplification, *HER2* gene mutation is a distinct entity in lung carcinogenesis with an incidence of 4.8% among *EGFR* wild-type lung adenocarcinoma resection samples \[[@CR6]\]. Drugs that target *HER2* gene mutations are currently being investigated. The National Comprehensive Cancer Network (NCCN) recommend trastuzumab or afatinib as potential therapy options for non-small cell lung cancers(NSCLC) patients with *HER2* mutations. Several phase I/II trials \[[@CR5], [@CR7]--[@CR9]\] is now investigating the efficacy of other irreversible pan-HER receptor family inhibitors, such as dacomitinib, neratinib and pyrotinib. Currently, *HER2* mutation is emerging as a promising druggable target, while the optimal choice of targeted therapy remains poorly defined.

Chemotherapy is still the standard first-line regimen for patients with advanced NSCLC who are improper for targeted therapy. Among them, pemetrexed-based regimen has showed superior efficacy with less side effects and was recommended preferentially for patients with adenocarcinomas \[[@CR10], [@CR11]\]. *ALK*/*ROS1*/*RET* positive patients showed a superior progression free survival(PFS) after pemetrexed-based therapy than patients with *KRAS* mutations \[[@CR12]--[@CR16]\]. While the effects of *HER2* mutation on the outcomes of pemetrexed-based chemotherapy is still unknown in patients with advanced NSCLC.

Aim to investigate the efficacy of pemetrexed-based chemotherapy in patients with *HER2*-mutant lung adenocarcinomas, we conducted this retrospective study in Chinese patients with 1714 advanced NSCLC. In addition, we also observed the clinicopathologic and molecular features of *HER2* mutations in patients with advanced NSCLC.

Methods {#Sec2}
=======

Patients population {#Sec3}
-------------------

Patients with advanced NSCLC (stage IIIB/IV) and performed *EGFR*, *ALK*, *ROS1*, *BRAF* and *KRAS* testing at Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China from January 2015 to September 2016 were included into this study. *HER2* mutations testing were performed in all these 5 genes pan-negative patients. Their clinical data were collected including age, gender, smoking status, tumor histology, performance status (PS) and the outcomes of anti-cancer therapies. Patients with *HER2*, *EGFR* or *KRAS* mutation or *ALK* or *ROS1* rearrangement and received first-line pemetrexed-based chemotherapy (pemetrexed monotherapy or combination therapy with platinum) were eligible for analysis. A history of radiotherapy, first-line targeted therapy, or immune-directed therapy was exclusionary.

Molecular testing {#Sec4}
-----------------

*HER2* mutation testing was performed using the method of amplification refractory mutation system(ARMS) by ADx HER2 Mutation Detection Kit (Amoy Diagnostics, Xiamen, China). Samples positive for *HER2* mutations were confirmed by DNA sequencing using primers with the following sequences: 5'GCC ATG GCT GTG GTT TGT GAT AGG3' (forward) and 5'ATC CTA GCC CCT TGT GGA CAT AGG3', which amplified a 342-bp fragment in exon20 of the *HER2* gene. The details can be referred to our previous study \[[@CR6]\].

Similarly, *EGFR*, *BRAF* and *KRAS* mutation were performed using EGFR, BRAF V600 and KRAS Mutations Detection Kit (Amoy Diagnostics, Xiamen, China) respectively by ARMS method. *ALK* and *ROS1* rearrangement testing were performed using AmoyDx EML4-ALK and ROS1 Fusions Detection Kit (Amoy Diagnostics, Xiamen, China) respectively by the method of reverse transcriptase polymerase chain reaction(RT-PCR). The details were described in our previous articles \[[@CR13], [@CR17]--[@CR19]\].

Statistical analysis {#Sec5}
--------------------

Tumor response was evaluated every 2 cycles of chemotherapy according to response evaluation criteria in solid tumors (version 1.1). PFS was defined as the time interval from the first day of treatment to documented disease progression or death of any cause. All of the statistical tests were performed using the SPSS 19.0. Chi-square test or Fisher's exact test was used to examine the clinicopathologic association of HER2 mutations and response rate comparison. Age differences were compared using the t test for independent samples or the one-way analysis of variance. The Kaplan--Meier method was used to estimate the PFS and the log-rank test was used to analyze PFS between the different groups. Results were considered significantly different if the *p* value was less than 0.05 in a two-way analysis.

Results {#Sec6}
=======

Patients' characteristics {#Sec7}
-------------------------

From January 2015 to September 2016, a total of 1714 patients with advanced NSCLC underwent testing for *EGFR*, *KRAS*, *BRAF*, *ALK* and *ROS1*.The results showed that there were 809 patients(47.2%) with *EGFR* mutations,149(7.8%) with *KRAS* mutations,19(1.1%) with *BRAF* mutations,106(6.2%) with *ALK* rearrangements, 43(2.5%) with *ROS1* rearrangements, and 16 patients (0.9%) with multiple positive results. In addition, 572 pan-negative patients also have tested their *HER2* status by ARMS and 29 (29/572,5.1%) were identified as *HER2* mutation positive (Fig [1](#Fig1){ref-type="fig"}).Fig. 1Mutations-testing results of 1714 patients with advanced non-small cell lung cancers.(multiple positive results 7EGFR&ALK, 1EGFR&ROS1, 2EGFR&KRAS, 2EGFR&BRAF, 2ALK&KRAS, 1ROS1&KRAS, 1EGFR&ROS1&KRAS)

*HER2*-mutant lung cancer patients had a median age of 58 (range 44--77 years) and mutations were more common in females (p\<0.001),non-smokers (*p* = 0.034) and adenocarcinomas (*p* = 0.002)(Table [1](#Tab1){ref-type="table"}). Twenty-four of 29 patients had available samples for sequencing and had the details variants of *HER2* mutation including 14 with exon20 A775_G776insYVMA, 3with P780_Y781insGSP, 3with G776 \> VC, 2with G776 \> IC, 1with G776 \> LC, and 1with G776C (Additional file [1](#MOESM1){ref-type="media"}: Figure S1).Table 1Clinical characteristics of patients with HER2-mutant lung cancersClinical characteristicsTotal (*n* = 572)HER2 negative (*n* = 543)HER2 positive (*n* = 29)*P* valueAge, years (median,range)64(27--92)64(27--92)58(44--77)0.017  \< 65305(53.3%)283(52.1%)22(75.9%)  ≥ 65267(46.7%)260(47.9%)7(24.1%)Gender Male430(75.2%)417(76.8%)13(44.8%)\<0.001 Female142(24.8%)126(23.2%)16(55.2%)Smoking status Non-smoker305(53.3%)284(52.3%)21(72.4%)0.034 Smoker267(46.7%)259(47.7%)8(27.6%)Histology Adenocarcinoma429(75%)400(74.0%)29(100%)0.002 Non-Adenocarcinoma143(25%)117(21.3%)0

Outcomes of chemotherapy: Comparison among oncogenic mutations groups {#Sec8}
---------------------------------------------------------------------

Patients received first-line pemetrexed-based chemotherapy were eligible for analysis(*n* = 25,14 combined with carboplatin, 7 combined with cisplatin and 4 monotherapy). Since most patients with druggable mutations chose TKI as a first-line treatment, only 74 of 809 *EGFR*-mutant patients and 39 of 149 *ALK*/*ROS1*-rearranged patients were included. While there were a relatively large number of patients with *KRAS* mutation, the first 40 of *KRAS* identified were selected for this study.

The baseline characteristics of patients with *HER2*-mutant were compared with patients with *EGFR*-mutant, *ALK*/*ROS1*-rearranged, and *KRAS*-mutant lung cancers as summarized in Table [2](#Tab2){ref-type="table"}. *HER2*, *EGFR*, *KRAS* mutations and *ALK*, *ROS1* rearrangements did not co-occur with each other in individual patient samples. *KRAS* mutations were more frequently detected in patients with more than 65 years old, male and smokers. And comparison revealed no significant differences in terms of PS score (*p* = 0.269), monotherapy versus combination therapy (*p* = 0.570), maintenance therapy versus non-maintenance therapy(*p* = 0.175).Table 2Baseline characteristics of patients treated with pemetrexed-containing chemotherapyClinical characteristicsHER2EGFRALK/ROS1KRAS*P* valueN25743940Age, years (median,range)55(44--77)58(27--80)54(37--77)64.5(33--80)0.002  \< 6521(84.0%)55(74.3%)28(71.8%)20(50.0%)  ≥ 654(16.0%)19(25.7%)11(28.2%)20(50.0%)Gender Male12(48.0%)37(50.0%)20(51.3%)33(82.5%)0.004 Female13(52.0%)37(50.0%)19(48.7%)7(17.5%)Smoking status Non-smoker18(72.0%)56(75.7%)29(74.4%)15(37.5%)\<0.001 Smoker7(28.0%)18(24.3%)10(25.6%)25(62.5%)PS 0--122(88.0%)68(91.9%)36(92.3%)32(80.0%)0.269  ≥ 23(12.0%)6(8.1%)3(7.7%%)8(20.0%)Therapy Monotherapy4(16.0%)9(12.2%)3(7.7%)9(22.5%)0.570 Plus carboplatin14(56.0%)42(56.8%)24(61.5%)23(57.5%) Plus cisplatin7(28.0%)23(31.1%)12(30.8%)8(20.0%) Maintenance therapy7(28.0%)18(24.3%)13(33.3%)5(12.5%)0.175 No maintenance18(72.0%)56(75.7%)26(66.7%)35(87.5%)

The response was evaluated in all 178 patients. Both the objective response rate(ORR) and the disease control rate (DCR) were not significantly different among four groups (Table [3](#Tab3){ref-type="table"}). However, PFS was significantly different among all groups. Patients in the *HER2*-mutant group had a median PFS of 5.1 months (95% confidence interval \[CI\], 4.90--5.30) (95% CI 4.90--5.30), which was numerically shorter than that of the *EGFR*-mutant group (6.5 months, 95% CI 4.48--8.52, *p* = 0.247) and significantly shorter than that of the *ALK*/*ROS1*-rearranged (9.2 months, 95% CI 6.41--11.99, *p* = 0.004). Similarly, in *KRAS*-mutant lung cancers, PFS (5.0 months, 95% CI 3.67--6.33) was inferior compared with *EGFR*-mutant (6.5 months, *p* = 0.242) and *ALK*/*ROS1*-rearranged (9.2 months, *p* = 0.007) lung cancers. PFS was not significantly different between the *HER2*-mutant and the *KRAS*-mutant lung cancers groups (5.1 vs 5.0 months, *p* = 0.971) (Fig.[2a](#Fig2){ref-type="fig"}).Table 3The objective response rate(ORR)and the disease control rate (DCR) of patients treated with pemetrexed-based therapy in four groupsHER2EGFRALK/ROS1KRAS*P* valuen25743940ORR%36.033.841.335.00.896DCR%92.078.487.272.50.139Fig. 2Progression-free survival time. **a**:Progression-free survival time of patients treated with pemetrexed-based therapy The "HER2" group were compared with the "EGFR", "KRAS" and "ALK/ROS1" groups. **b**: Progression-free survival time of patients with HER2-mutant lung adenocarcinomas treated with pemetrexed-based therapy. The A775_G776insYVMA group were compared with the other variants group (*n*=7, 3with P780_Y781insGSP, 2with G776\>IC, 1with G776\>LC, and 1with G776C)

Outcomes of chemotherapy: Comparison among HER2 variants subgroups {#Sec9}
------------------------------------------------------------------

Twenty patients of the 25 patients receiving first-line pemetrexed-based chemotherapy had known HER2 variants (Additional file [1](#MOESM1){ref-type="media"}: Figure S1). According to the frequency of the variants, they were divided into the exon20 A775_G776insYVMA group (*n* = 13) and the other variants group (*n* = 7, 3with P780_Y781insGSP, 2with G776 \> IC, 1with G776 \> LC, and 1with G776C). PFS has a trend to be inferior in the YVMA group, even though no statistically significant difference existed between the 2 groups (4.2 vs 7.2 months, *p* = 0.085) (Fig [2b](#Fig2){ref-type="fig"}).

Discussion {#Sec10}
==========

As far as we know, this study is the first study to compare the efficacy of pemetrexed-based chemotherapy between *HER2*-mutant and groups of *EGFR*-mutant, *ALK*/*ROS1*-rearranged and *KRAS*-mutant lung adenocarcinoma. We found that patients with *HER2*-mutant lung cancers had a PFS of 5.1 months that was similar with *KRAS*-mutant (5.0 months, *p* = 0.971) lung cancers, and numerically shorter than *EGFR*-mutant (6.5 months, *p* = 0.247) and significantly shorter than *ALK*/*ROS1*-rearranged (9.2 months, *p* = 0.004) lung cancers, showing that *HER2*-mutant lung cancer patients may have poor outcomes with chemotherapy, which strengthen the importance of developing HER2-targeted drugs in this population. We also investigate the clinicopathologic features in patients with advanced *HER2*-mutant lung adenocarcinomas and found that *HER2* mutations were more common in younger patients, females, non-smokers and adenocarcinomas.

Different from HER2 over-expression and amplification, *HER2* mutations was found to be a distinct entity in patients with NSCLC \[[@CR20]\]. *HER2* mutations are found in about 1%--2% of NSCLC \[[@CR20]--[@CR22]\]. In this study, the incidence of *HER2* mutations was 5.1% in *EGFR*/*KRAS*/*BRAF*/*ALK*/*ROS1* negative patients, indicating that *HER2* mutations will be enriched in the population without other driver gene mutations. Consistent with our study, a study from the Memorial Sloan Kettering Cancer Center (MSKCC) group \[[@CR23]\] showed that in a selected population with *EGFR*/*KRAS*/*ALK* negative, the incidence of *HER2* mutations can reach up to 6%. In the early stage resection samples, our previous study \[[@CR6]\] showed that the presence of HER2 mutations was not correlated with gender, age, or smoking status. However, another retrospective study \[[@CR24]\] of resection samples obtained at Fudan University Shanghai Cancer Center found that the incidence of HER2 mutations can reach up to 5.94% in non-smoking patients with lung adenocarcinoma. Similarly, in biopsied samples from advanced NSCLC, our study showed that *HER2* mutations were more common in non-smokers and lung adenocarcinomas. But *HER2* mutations were also frequently detected in younger patients and females in our study. Furthermore, exon20 A775_G776insYVMA was the most frequently alteration.

In the era of targeted therapy, several oncogenic driver mutations were found not only could predict the efficacy of targeted therapy, but also associated with superior outcome of first line pemetrexed chemotherapy, such as *ALK*, *ROS1* and *RET* \[[@CR12]--[@CR16]\]. Thus, we further investigate the association of *HER2* mutation with the efficacy of pemetrexed-based chemotherapy in patients with advanced lung adenocarcinomas. We found that patients with *HER2*-mutant lung cancers had a PFS of 5.1 months. Similar to this study, in the EUHER2 study \[[@CR25]\] of patients with *HER2*-mutant lung cancers, ORR and PFS with chemotherapy were 43.5% and 6 months in first-line and 10% and 4.3 months in second-line therapies. Our study also showed that *HER2*-mutant lung cancers had a similar PFS of pemetrexed-based chemotherapy with *KRAS*-mutant lung cancers (5.0 months), which was inferior compared with *EGFR*-mutant(6.5 months) and *ALK*/*ROS1*-rearranged (9.2 months), indicating that *HER2* mutation might predict a poor efficacy of pemetrexed-based chemotherapy, just like *KRAS* mutation. Although pemetrexed-based chemotherapy had the longest duration among chemotherapies(pemetrexed/taxane/gemcitabine/vinorelbine/etoposide±platinum) for patients with *HER2* mutations according to Eng et al's study \[[@CR26]\] and Gow et al's study \[[@CR27]\], outcomes of pemetrexed for *HER2* were poor compared to other oncogene subgroups,such as *ALK* and *ROS1*. Furthermore, we further divide *HER2* mutations into the exon20 A775_G776insYVMA group and the other variants group and it was the first time that we found that patients with YVMA insertion were associated with an inferior PFS (4.2 vs 7.2 months, *p* = 0.085).

Currently, NCCN guideline recommend trastuzumab and afatinib as the targeted therapeutic options for patients with advanced *HER2*-mutant NSCLC. While, in EUHER2 study \[[@CR25]\], afatinib showed a modest response of 18.2% and median PFS of 3.9 months even though this drug has showed response in all 3 assessable patients with *HER2*-mutant adenocarcinoma in a preliminary study \[[@CR28]\]. Meanwhile, several other studies \[[@CR5], [@CR7], [@CR8]\] investigated the efficacy of other irreversible pan-HER receptor family inhibitors, dacomitinib, neratinib, or neratinib combining with mTOR inhibitors in advanced NSCLC patients harboring *HER2* mutations and showed a moderate response of 12%--21%. Although these ORR or PFS are much diminished compared with those of TKIs directed at other targets in NSCLC, HER2-targeted drugs is still promising. A phase II study recently investigated a novel EGFR/HER2 inhibitor, pyrotinib, in heavily pre-treated patients with *HER2*-mutant adenocarcinomas and found a promising results with RR of 54.5%(6/11) and median PFS of 6.2 months \[[@CR9]\]. Large number cohort study is still needed to validate the efficacy of pyrotinib in this setting.

Our study does have several limitations. First, it was a retrospective study with limited patients number(*n* = 25), while this study presented the real world nature in Chinese population. Second, *HER2* mutation testing was performed using the method of ARMS, thus some rare mutations might be missed in our population. Next generation sequencing (NGS), which allows for simultaneous testing for multiple mutations using one platform and one sample, is emerging as an important method for identification of gene mutations in NSCLC, but single-gene sequencing is still more widely used. Thirdly, a substantial part of the patients with *HER2* mutations also participant into the previous clinical trial of HER2-targeted drugs \[[@CR9]\], thus the overall survival might be heavily influenced by the subsequent therapy.

Conclusions {#Sec11}
===========

In conclusion, *HER2* mutations were more frequent happened in younger patients, females, non-smokers and adenocarcinomas of advanced NSCLC. Patients with *HER2*-mutant lung adenocarcinomas, especially YVMA insertion, showed poor response to pemetrexed-based chemotherapy. Thus, developing HER2-targeted drugs to improve their poor prognosis is urgently needed for this population.

Additional file
===============

 {#Sec12}

Additional file 1:**Figure S1.** Study flow chart. (PDF 160 kb)
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